Danielle Dray

Appearances

ETRASIMOD INDUCTION THERAPY IN MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE: RESULTS FROM A PHASE 2, RANDOMIZED, DOUBLE-BLIND SUBSTUDY
Date
May 9, 2023
BACKGROUND: After successful induction, a subset of patients with Crohn’s disease (CD) experience a secondary loss of response (LoR) to ustekinumab (UST) maintenance therapy. Dose intensification may assist in regaining response…
Presenter
Geert D’Haens
Speakers
Marla Dubinsky
Icahn School of Medicine, Mount Sinai
Laurent Peyrin-Biroulet
Silvio Danese
Bruce Sands
Douglas Wolf
Andres Yarur
Michael Chiorean
Swedish Medical Center
Danielle Dray
Irene Modesto
Huaming Tan
Guibao Gu
Claudia Lopez
Chinyu Su
Jinkun Zhang
Aoibhinn McDonnell
Stefan Schreiber
Brian Feagan
Western University
Séverine Vermeire
Katholieke Universiteit Leuven Universitaire Ziekenhuizen Leuven